Scientific Goals The mission of the HDFCCC Tobacco Control (TO) Program is to reduce the burden of cancer caused by tobacco, locally, in the catchment area, and globally. This mission is advanced through robust Program themes reaching from the molecular level of tobacco-induced disease, to the physical and medical health effects of tobacco, to individual and community tobacco cessation efforts, and to policy and regulatory actions at state, national, and global levels. Theme 1: Biological determinants of tobacco-induced addiction and disease Theme 2: Social and behavioral determinants and interventions for tobacco addiction Theme 3: The tobacco industry as a disease vector and strategies to block it TO Program: Key Metrics Membership (9 departments, 4 schools) 28 Full 14 Associate 14 Cancer-relevant Funding (direct costs as of $9,353,958 05/31/2017) NCI $2,506,751 27% Peer-reviewed $4,804,645 51% Non-peer-reviewed $2,042,562 22% Cancer-relevant Publications (1/2012-7/2017) 492 Inter-programmatic 16 3% Intra-Programmatic 127 26% High-Impact 255 52% Accruals to Clinical Trials (2016) 7350 20 Therapeutic 0 0 Other Interventional 75 4 Non-interventional 7275 16
| Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
| Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
| Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
| An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications
